New mRNA vaccine takes on solid tumors in early trial
NCT ID NCT03313778
First seen Dec 24, 2025 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This early-phase study tests an experimental mRNA cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy drug pembrolizumab. The main goal is to check safety and immune response, not yet to prove the vaccine cures cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9416, United States
-
Imperial College Healthcare NHS Trust Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Kindai University Hospital
Osakasayama-Shi, Ôsaka, 589-0014, Japan
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU Langone Medical Center
New York, New York, 10016, United States
-
National Cancer Center East
Kashiwa-Shi, Chiba, 277-8577, Japan
-
National Cancer Center Hospital
Chuo-Ku, Tokyo, 104-0045, Japan
-
Ninewells Hospital - PPDS
Dundee, Scotland, DD1 9SY, United Kingdom
-
One Clinical Research Perth
Nedlands, Western Australia, 6009, Australia
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Royal Mardsen Sutton
Sutton, Surrey, SM2 5PT, United Kingdom
-
St Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia
-
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Tokyo, 135-8550, Japan
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195-0001, United States
-
The George Washington Cancer Center
Washington D.C., District of Columbia, 20037, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15219, United States
-
UT Southwest Medical Center
Dallas, Texas, 75390, United States
-
Westmead Hospital-Cnr Hawkesbury and Darcy Road
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.